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Heterozygous Loss-of-Function Mutations
in DLL4 Cause Adams-Oliver Syndrome
Josephina A.N. Meester,1 Laura Southgate,2 Anna-Barbara Stittrich,3 Hanka Venselaar,4
Sander J.A. Beekmans,5 Nicolette den Hollander,6 Emilia K. Bijlsma,6
Appolonia Helderman-van den Enden,6,16 Joke B.G.M. Verheij,7 Gustavo Glusman,3 Jared C. Roach,3
Anna Lehman,8 Millan S. Patel,8 Bert B.A. de Vries,9 Claudia Ruivenkamp,6 Peter Itin,10
Katrina Prescott,11 Sheila Clarke,12 Richard Trembath,2 Martin Zenker,13 Maja Sukalo,13 Lut Van Laer,1
Bart Loeys,1,14,15,* and Wim Wuyts1,15,*
Adams-Oliver syndrome (AOS) is a rare developmental disorder characterized by the presence of aplasia cutis congenita (ACC) of the
scalp vertex and terminal limb-reduction defects. Cardiovascular anomalies are also frequently observed. Mutations in five genes
have been identified as a cause for AOS prior to this report. Mutations in EOGT and DOCK6 cause autosomal-recessive AOS, whereas
mutations in ARHGAP31, RBPJ, and NOTCH1 lead to autosomal-dominant AOS. Because RBPJ, NOTCH1, and EOGT are involved in
NOTCH signaling, we hypothesized that mutations in other genes involved in this pathway might also be implicated in AOS pathogen-
esis. Using a candidate-gene-based approach, we prioritized DLL4, a critical NOTCH ligand, due to its essential role in vascular develop-
ment in the context of cardiovascular features in AOS-affected individuals. Targeted resequencing of the DLL4 gene with a custom
enrichment panel in 89 independent families resulted in the identification of seven mutations. A defect in DLL4 was also detected in
two families via whole-exome or genome sequencing. In total, nine heterozygous mutations in DLL4 were identified, including two
nonsense and seven missense variants, the latter encompassing four mutations that replace or create cysteine residues, which are
most likely critical for maintaining structural integrity of the protein. Affected individuals with DLL4 mutations present with variable
clinical expression with no emerging genotype-phenotype correlations. Our findings demonstrate that DLL4 mutations are an addi-
tional cause of autosomal-dominant AOS or isolated ACC and provide further evidence for a key role of NOTCH signaling in the etiology
of this disorder.Adams-Oliver syndrome (AOS [MIM: 100300]) is a rare
developmental disorder with an estimated incidence of 1
in 225,000 live births.1 It is typically characterized by the
presence of both aplasia cutis congenita (ACC) of the scalp
vertex and terminal limb defects, such as brachydactyly,
oligodactyly, syndactyly, hypoplastic nails, or transverse
amputations.2 In addition, vascular and cardiac anomalies,
comprising pulmonary hypertension, ventricular septum
defects, tetralogy of Fallot, and anomalies of the great ar-
teries and their valves are frequently observed.2 In the
past few years, mutations in five genes have been described
as a cause of AOS. Mutations in EOGT (MIM: 615297) and
DOCK6 (MIM: 614219) cause the autosomal-recessive form
of AOS, whereas mutations in ARHGAP31 (MIM: 100300),
RBPJ (MIM: 614814), and NOTCH1 (MIM: 616028) lead to
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The Americanand RBPJ are all members of the NOTCH signaling
pathway. This pathway is conserved throughout metazoan
species and is involved in many different tissue-specific
cellular processes, including cell-fate determination and
neural and hematopoietic stem cell differentiation.9,10
The NOTCH receptors and ligands are composed of several
domains, including epidermal growth factor (EGF)-like do-
mains. EOGT is an EGF domain-specific O-linked N-acetyl-
glucosamine (GlcNAc) transferase known to glycosylate
NOTCH1 and is therefore highly likely to influence
NOTCH signaling through post-translational modification
of the extracellular EGF-like repeats.4,10,11 RBPJ is a
sequence-specific transcription factor that regulates the
transcriptional activity of downstream target genes by
binding to the intracellular domain of NOTCH, leading
to the recruitment of additional proteins.12 In additionsity of Antwerp and Antwerp University Hospital, Antwerp, 2650, Belgium;
ity of London, Charterhouse Square, London, EC1M 6BQ, UK; 3Institute for
d Biomolecular Informatics, Radboud Institute for Molecular Life Sciences,
partment of Plastic and Reconstructive Surgery, VU Medical Center Amster-
ics, Leiden University Medical Center, Leiden, 2333 ZA, the Netherlands;
niversity of Groningen, Groningen, 9700 RB, the Netherlands; 8Department
itish Columbia, Vancouver, BC, V6H 3N1, Canada; 9Department of Human
University Medical Centre, Nijmegen, 6500 HB, the Netherlands; 10Depart-
Department of Clinical Genetics, Chapel Allerton Hospital, Leeds, LS7 4SA,
UK; 13Institute of Human Genetics, Otto-von-Guericke-Universita¨t Magde-
artment of Genetics, Radboud University Medical Center, Nijmegen, 6525
e (W.W.)
y of Human Genetics. All rights reserved.
Journal of Human Genetics 97, 475–482, September 3, 2015 475
to causing AOS, mutations in NOTCH1 are also known to
cause bicuspid aortic valve and thoracic aortic aneu-
rysm.13 NOTCH signaling is activated by two families of
ligands, namely Jagged (JAG1 or JAG2) and Delta (DLL1,
DLL3, or DLL4). Of these, DLL4 has an essential role in
vascular development and angiogenesis, which places it
as a prime candidate for AOS, due to the presence of cardio-
vascular features in AOS-affected individuals.14,15
The study was approved by the appropriate institutional
review board, and appropriate informed consents were
obtained from human subjects. We performed targeted
resequencing of DLL4 on 89 individuals by using HaloPlex
Targeted Enrichment (Agilent Technologies) followed by
sequencing on MiSeq (Illumina) with 150 bp paired-end
reads. An in-house-developed Galaxy-based pipeline
was used to process the raw data.16 Variant calling was
performed with the Genome Analysis Toolkit Unified
Genotyper,17 and variants were annotated and filtered
with the in-house-developed database VariantDB.18 We
selected unique variants or variants present in the
ESP6500 and 1000 Genomes databases with a MAF<1%,
prioritizing nonsense, nonsynonymous, splice-site, and
indel variants in both a dominant and a recessive model.
Separately, whole-genome sequencing (WGS) was
performed on family 2, and whole-exome sequencing
(WES) was performed on family 6. Genomic DNA was
extracted from saliva from the two affected siblings of
family 2 and subjected to the Agilent SureSelect Target
Enrichment (v.4; 51 Mb) capture process. After library
preparation, sequencing was performed on the Illumina
HiSeq2000, generating 100 bp paired-end reads. Over
97.5% of target regions were covered by >103. Reads
were mapped against reference genome UCSC hg19 with
the Burrows-Wheeler Aligner. Single-nucleotide variants
and indels were detected by SAMtools. WES on family 6
was performed as previously described.7 All variants
were confirmed by bidirectional Sanger sequencing, and
segregation analysis was performed on available family
members.
In total, we screened 91 families and identified nine
DLL4 (GenBank: NM_019074.3) heterozygous variants
(with GRCh37 as a reference build), including nonsense,
cysteine-replacing or -creating, and other missense sub-
stitutions (Figure 1, Table S1). These results designate
mutations in this gene as an additional cause of an auto-
somal-dominant form of AOS.
In two families, we detected nonsense mutations
in exon 9 of DLL4, specifically c.1660C>T (p.Gln554*
[ClinVar: SCV000240088]) in family 1 and c.1672C>T
(p.Arg558* [ClinVar: SCV000240089]) in family 2. Both
stop-gain mutations are predicted to lead to nonsense-
mediated decay (NMD) of the mutant mRNA transcript
(Figure 1B).19 The severity of the clinical features in
the affected family members of both families varied
widely and included ACC, syndactyly, and brachydactyly
(Figure 2, Table 1). In the proband of family 1 (1-III-3),
cardiovascular features were also present, namely tricuspid476 The American Journal of Human Genetics 97, 475–482, Septembinsufficiency and ventricular septum defect (Table 1).
Molecular screening of available family 1members showed
segregation of the mutation in the affected sister (1-III-1)
and mother (1-II-2) and absence of the mutation from
the unaffected father (1-II-1) and maternal grandmother
(1-I-2). Interestingly, the mutation was not detected in
the maternal grandfather (1-I-1), who presented with uni-
lateral brachydactyly of the toes (III and IV). We failed to
demonstrate the possibility of somatic mosaicism in his
blood by a mutation-allele-specific PCR. Nevertheless,
somatic mosaicism not affecting the hematopoietic tissue
remains a plausible explanation. In family 2, the affected
sister (2-II-1) also carried the mutation. Mutation analysis
of the parents showed that c.1672C>T was inherited
from the father (2-I-1), who did not show obvious signs
of AOS. DNA of the paternal grandparents was not avail-
able to allow us to investigate whether the mutation in
the father occurred de novo.
In addition to the two stop-gainmutations, we identified
seven different heterozygous missense mutations: three
cysteine-replacing mutations, one cysteine-creating muta-
tion, and three other missense mutations. All identified
missense mutations were predicted to be damaging by
MutationTaster, PolyPhen-2, and SIFT, and none of the
mutations were present in the following public databases:
ESP6500, Kaviar,20 1000 Genomes, and ExAC.
In families 3, 4, and 5, cysteine-replacing mutations
(c.1365C>G, p.Cys455Trp [ClinVar: SCV000240090];
c.1169G>A, p.Cys390Tyr [ClinVar: SCV000240091]; and
c.1168T>C, p.Cys390Arg [ClinVar: SCV000240092],
respectively) in exons 8 and 9 of DLL4 were identified.
All of these mutations affect critical and highly conserved
(up toD. melanogaster) cysteines of the consensus sequence
of either the 5th or 7th EGF-like domain (Figure 1C). Similar
to the features noted in those affected by the nonsensemu-
tations, the severity of the clinical features of all available
affected family members varied greatly, but all showed
scalp involvement, including ACC or a bald scalp area
(Table 1, Figure 2). The c.1365C>G (p.Cys455Trp) muta-
tion, identified in the proband of family 3 (3-II-1), was
confirmed in the affected mother (3-I-2) and in a sister
(3-II-2), but no clinical information of the latter was avail-
able. We found a mutation replacing the cysteine residue
at position 390 but leading to different amino acid sub-
stitutions in both family 4 (c.1169G>A, p.Cys390Tyr)
and family 5 (c.1168T>C, p.Cys390Arg). The proband of
family 4 (4-II-1) showed isolated ACC, and no family
members were available for screening. The proband of
family 5 (5-IV-3) is part of a large family with multiple
affected individuals. The father (5-III-3) and two great
aunts (5-II-14 and 5-II-17) carried the c.1168T>Cmutation
(Figure 1A). They were all only mildly affected, but did
have severely affected offspring (Table 1, Figure 2), further
illustrating the highly variable clinical expression for
DLL4-associated AOS.
In theprobandof family6 (6-II-1),wedetectedaheterozy-
gous cysteine-creating mutation: c.556C>T (p.Arg186Cyser 3, 2015
Figure 1. Mutation Analysis
(A) Pedigrees of the families with their respective mutations and nucleotide sequences.
(B) Structure of DLL4 with the structural domains and the identified mutations.
(C) Conservation of specific residues among species and NOTCH ligands.[ClinVar: SCV000240093]). The affected family members
bothexhibited isolatedACC(Table1, Figure2). Thearginine
at this position is conserved between DLL4 and DLL3 and
is conserved across mammalian species (Figure 1C). TheThe Americanaffected father (6-I-1) carried themutation, whereas the un-
affected mother (6-I-2) did not.
In families 7, 8, and 9, we found missense variants
(c.799C>A, p.Pro267Thr [ClinVar: SCV000240094];Journal of Human Genetics 97, 475–482, September 3, 2015 477
Figure 2. Clinical Features
(A) Individual 2-II-1 with brachydactyly of
the left foot and missing toes on the right
foot.
(B) Individual 5-II-17 with a bald area on
the scalp.
(C) Individual 5-II-17 with brachydactyly
of toes.
(D) Individual 5-II-17 with brachydactyly
of fingers.
(E) Individual 5-IV-12 with aplasia cutis
congenita.
(F) Individual 6-II-1 with aplasia cutis
congenita.
(G) Individual 8-II-1 with short distal
phalangus of the middle finger and sym-
phalangism of the index finger on the
right hand.
(H) Individual 8-II-1 with aplasia cutis
congenita.
(I) Individual 8-II-1 with symbrachydactyly
of both feet.c.361G>C, p.Ala121Pro [ClinVar: SCV000240095]; and
c.583T>C, p.Phe195Leu [ClinVar: SCV000240096],
respectively) affecting specific residues in functional
domains of DLL4; these residues are conserved up to
D. melanogaster and in the four most closely related
NOTCH-receptor ligands, namely JAG1, JAG2, DLL1, and
DLL4 (Figure 1C). Both families 7 and 8 presented with
scalp defects, limb defects, and cardiovascular features
(Table 1, Figure 2). The parents of proband 7 were reported
as unaffected, but the mother (7-I-2), who was a mutation
carrier, has a positive family history for cardiac events; this
history includes a brother with bicuspid aortic valve with
narrowed aorta ascendens and a maternal half-brother
who died at birth of an unspecified heart defect. Unfortu-
nately, DNA of the maternal grandparents or other family
members was not available. In the proband of family 8
(8-II-1), the c.361G>C (p.Ala121Pro) mutation was
shown to be de novo, given that both unaffected parents
did not carry the mutation (Figure 1A). The index of family
9 has been described before and shows only ACC.21 In
this individual, we identified a heterozygous c.583T>C
(p.Phe195Leu) variant. No further information of familial
occurrence was available.
The DLL4 variants are distributed across the complete
protein, affecting all known structural domains (MNNL
[N-terminal domain of NOTCH ligands], DSL [Delta/478 The American Journal of Human Genetics 97, 475–482, September 3, 2015Serrate/Lag-2], and EGF-like domains),
without any obvious mutational hot-
spots. Recently, the structural basis
of the interaction between NOTCH1
and DLL4 has been elaborated.10 The
binding of NOTCH1 to DLL4 is co-
ordinated by the interaction between
the NOTCH1 EGF-like domain 11
and the DLL4 DSL domain. DLL4-
NOTCH1 binding is further modu-latedby the interactionbetweenNOTCH1EGF-like domain
12 and the MNNL domain of DLL4. Glycosylation of
NOTCH1 is essential and specific for the binding of
DLL4.10
Three-dimensional modeling predictions of our DLL4
mutations reveal interesting changes in protein confor-
mation and amino acid functionality (Figure S1). In
total, three cysteine-replacing pathogenic variants have
been found, two at position 390 (p.Cys390Arg and
p.Cys390Tyr), located in the EGF-like domain 5, and one
at position 455 (p.Cys455Trp), located in the EGF-like
domain 7. In their respective EGF domains, all three cyste-
ines are involved in the formation of a disulfide bond,
which will be lost due to the introduction of these patho-
genic variants. Furthermore, both arginine and tyrosine
residues at position 390 are too bulky to fit in this domain
and are therefore likely to disrupt the structure. Hence,
structural changes are predicted to occur, which will
most likely lead to a loss of function of DLL4.
Both phenylalanine at position 195 and arginine at
position 186 are located in the DLL4 DSL domain
(Figure 1B), a conserved central domain directly involved
in ligand binding to the EGF-like domain 11 of the
NOTCH1 receptor.10 It has been shown that the phenylal-
anine at position 195 is a key interface residue important
for binding, and when mutated to an alanine residue,
Table 1. Clinical Features
Individual
Internal
Reference
Mutation
Status
Clinical Features
Scalp Defects Limb Defects Cardiovascular Features Other Remarks
1-I-1 SK039  / left brachydactyly
of 3rd and 4th toes
(confirmed by X-ray)
/ /
1-II-2 SK039 þ / short distal phalanges
(not confirmed by X-ray)
/ /
1-III-1 SK039 þ ACC / normal echocardiogram /
1-III-3 SK039 þ ACC brachydactyly, syndactyly
of 2nd and 3rd toes
on right foot
tricuspid insufficiency,
ventricular septum defect
/
2-II-1 F45 þ ACC with
underlying
skull defect
brachydactyly left foot,
missing toes on right foot
normal echocardiogram /
2-II-3 F45 þ ACC with
underlying
skull defect
brachysyndactyly of
right foot, severe
brachysyndactyly
of left foot
normal echocardiogram small kidneys,
mild hypertension
3-I-2 SK038 þ ACC / / /
3-II-1 SK038 þ ACC / / /
4-II-1 SK049 þ ACC / / /
5-II-4 SK087 no DNA ACC syndactyly of 2nd and
3rd toes, hypoplastic
toe nails, brachydactyly
of toes
/ /
5-II-14 SK087 þ bald area on scalp / / cutis marmorata
5-II-17 SK087 þ bald area on scalp brachydactyly of fingers
and toes, syndactyly
of 2nd and 3rd toes
/ /
5-III-3 SK087 þ bald area on scalp / / /
5-III-21 SK087 no DNA bald area on scalp / / /
5-III-23 SK087 no DNA ACC with
underlying
skull defect
/ / /
5-IV-3 SK087 þ ACC / normal echocardiogram cutis marmorata, epilepsy,
learning difficulties,
borderline intellectual
function (TIQ 76) at
young age, normal IQ
at later age, mild
periventricular leukomalacia
5-IV-12 SK087 no DNA ACC / normal echocardiogram,
portal hypertension,
esophageal varices
splenomegaly, congenital
liver fibrosis
6-I-1 UK16 þ ACC / no cardiac problems /
6-II-1 UK16 þ ACC / normal echocardiogram /
7-I-2 SK082 þ / / / unaffected
7-II-1 SK082 þ ACC, delayed
ossification
hypoplastic toe nails no cardiac problems cutis marmorata,
normal chest X-ray
at age of 2 months
8-II-1 SK081 þ ACC short distal phalangus of
middle finger on the right
hand, symphalangism of the
index finger, symbrachydactyly
of both feet
truncus arteriosus,
ventricular septum
defect
growth hormone deficiency
9-II-1 SK013 þ ACC / / /
Abbreviations are as follows: þ, present; , absent; ACC, aplasia cutis congenita; /, unknown.
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it results in a substantial decrease in NOTCH1 interac-
tion.10 The p.Arg186Cys pathogenic variant is located in
the surface loop of the DSL domain. The introduction
of a cysteine at this location is not expected to cause
steric hindrance; however, the important interaction
function of the Arginine186 residue is likely to be lost. In
addition, this mutation creates a cysteine, which could
dramatically alter the conformation of the protein by
forming a novel disulfide bond. Both these DSL domain
mutations will likely reduce the binding affinity of DLL4
to NOTCH1.
The Alanine121 residue is located in a beta-strand on the
inside of the MNNL domain. Together with the DSL
domain, the MNNL domain is involved in the binding of
the ligand to EGF-like domain 12 of the NOTCH-receptor
and regulates ligand pleiotropy.10 The replacement of
Alanine 121 by proline is predicted to disrupt the local
structure and function.
Lastly, the Proline267 residue is located in EGF-like
domain 2 and makes contact with EGF-like domain 1 in
a surface loop. This interactionmight be altered by the sub-
stitution to threonine.
The discovery ofDLL4mutations in our AOS-affected in-
dividuals, in addition to prior identification of mutations
in EOGT, RBPJ, and NOTCH1, confirms the key role of
the NOTCH signaling pathway in the pathogenesis of
AOS. Activation of NOTCH signaling through binding
of a NOTCH ligand (JAG1, JAG2, DLL1, DLL3, or DLL4)
to one of the NOTCH receptors (NOTCH1, NOTCH2,
NOTCH3, or NOTCH4) results in two proteolytic cleavage
reactions performed by a member of the ADAM (a disinte-
grin and metalloproteinase domain-containing protein)
family and by the ү-secretase complex. The second cleav-
age releases the intracellular domain of NOTCH, NICD,
which is translocated to the nucleus, where it binds to
the coactivator mastermind ligand (MAML) and the DNA
binding protein RBPJ to induce transcription of NOTCH
target genes.22
DLL4 is a ligand of the NOTCH receptors and is essential
for vascular development.12 During embryonic develop-
ment, protein localization of DLL4 is restricted to the large
arteries, whereas in adult stages, the protein is also present
in the smaller arteries and microvessels. Haploinsuffi-
ciency of Dll4 in mice results in embryonic lethality as
a result of profound defects in vascular and arterial devel-
opment.15 In contrast to what occurs in mice models,
human haploinsufficiency of DLL4 does not result in
lethality given that we have identified two heterozygous
nonsense mutations, which most likely lead to NMD.19
The lethality in mice could be related to the inbred genetic
background of the mice23 and potential functional differ-
ences in redundancy between humans and mice. The
identification of both DLL4 nonsense mutations and
several missense mutations in key functional domains of
DLL4 that are predicted to disrupt DLL4 integrity suggests
that loss of function is the pathogenetic mechanism.
Despite DLL4 being described as being essential for480 The American Journal of Human Genetics 97, 475–482, Septembvascular development,12 not all individuals with DLL4mu-
tations presented with cardiovascular features (Table 1),
although complete cardiovascular exams have not been
performed in all cases.
We did not observe a clear genotype-phenotype correla-
tion between DLL4 mutation and AOS subtype. Further-
more, we observed marked intrafamilial variability in
the phenotypic expression. For example, in family 5, the
p.Cys390Arg substitution leads to a severe phenotype in
the offspring, whereas the parents show isolated ACC.
This suggests that other factors are involved in the clinical
expression of this disease; these factors could be environ-
mental, but also other genetic and epigenetic influences
involved in the NOTCH signaling pathway or other AOS
related pathways. In addition to the variable clinical
expression, we also observed incomplete penetrance in
families 2 and 7, and additional unidentified asymptom-
atic mutation carriers may exist in other families. Highly
variable expressivity and incomplete penetrance, as well
as the association with cardiovascular abnormalities, are
similar to what has been observed in NOTCH1-related
AOS.7,8 In contrast, cerebral and ocular abnormalities,
which have been found to be particularly associated with
autosomal-recessive DOCK6-related AOS, appear to be un-
common in those autosomal-dominant forms.24
In conclusion, through screening a cohort of 91 families
affected with AOS or ACC, we have identified nine hetero-
zygous variants in DLL4, including nonsense, cysteine-
replacing or -creating, and other missense mutations,
demonstrating that mutations in this gene are an impor-
tant cause of autosomal-dominant AOS or isolated ACC.
Affected individuals show variable clinical expression
with no clear genotype-phenotype correlations at present.
With the addition ofDLL4, four genes involved in NOTCH
signaling have now been implicated in AOS, confirming
that disruption of this pathway plays a major role in the
pathogenesis of AOS.Accession Numbers
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